Japan’s Strategic Edge in Pharmaceutical Patent Term Extensions: A Comparative Analysis in Japan, the U.S. and EU

For those who develop and commercialize new pharmaceuticals, maximizing product value is a key concern. While there are multiple factors involved in maximizing value, the exclusive rights to protect the product granted by patent and pharmaceutical laws are among the most important.

This position paper outlines the differences in patent term extension systems among Japan, the U.S., and EU, and examines whether any of these systems holds a competitive advantage. It explains that Japan’s system is designed to provide robust protection for both sequential and cumulative innovation, thereby offering a more favorable competitive environment than those in the U.S. and EU.

Introduction

First, I will briefly explain why the patent term extension system for pharmaceuticals exists. Then, I will try to draw a conclusion as to which one offers the greatest advantage by comparing the systems in Japan, the U.S. and EU.

Key points to Consider

1. What exactly is the patent term extension system for pharmaceuticals? Why can only pharmaceuticals have their patents extended?

In principle, patents last 20 years from the date of application. However, clinical trials and approval reviews often take more than 10 years, resulting in a long period during which the product cannot be commercialized despite having a patent. Therefore, the patent extension system is designed to compensate for that period when the product couldn’t be commercialized.

2. A Comparison of Systems in Japan, the U.S., and EU

3. Outlining Each Country’s System

Japan: Innovation-Focused and Highly Favorable to Originators

Japan is often viewed as the most advantageous system for originator companies due to several key features.

Key Characteristics

• Patent term extensions of up to 5 years
• Extensions apply not only to initial approval, but also to:
  • Addition of indications
  • New dosage forms
  • New methods of administration
• No fixed upper limit on total patent term following approval

In practice, there are cases where patents remain in effect for a very long time.

Why This Is Advantageous

• Ongoing development activities increase the likelihood of additional extensions
• The scope of an extended patent can be difficult for generic manufacturers to interpret

Impact

These factors often lead to prolonged market exclusivity. Overall, Japan’s system is strongly rooted in maximizing protection for innovative pharmaceuticals.

United States: A Balanced Approach Between Innovation and Competition

The U.S. system reflects a compromise between supporting innovation and enabling earlier generic entry.

Key Characteristics

• • PTE governed by the Hatch-Waxman Act
  • Extensions are limited to one patent per product
  • Maximum extension of 5 years
  • Total effective patent life capped at 14 years from FDA approval
    

Supporting Framework

• Abbreviated New Drug Application (ANDA) pathway for accelerated generic entry
• FDA Orange Book, which provides transparency on patent status
• Paragraph IV Patent Challenges, allowing generics to contest patents prior to expiry

Impact

In exchange for limited patent extensions, the system actively facilitates earlier generic competition. The U.S. model reflects a deliberate balance between incentivizing innovation and controlling healthcare costs.

European Union: Structured, Transparent, and Competition-Oriented 

The EU employs a more rigid and complex framework centered on transparency and market competition.

Key Characteristics

• Supplementary Protection Certificates (SPCs) are not “patent extensions” but a separate right that arises after patent expiration
• Maximum duration of up to 5 years
• Applies only to the first marketing authorization
• Total protection capped at 15 years from approval

Additional Considerations

• Recent policy updates, including manufacturing waivers and stockpiling permits, have led to amendments that accommodate generics

Impact

The EU system emphasizes predictability and competition, offering more limited flexibility for originators compared to Japan or the U.S.

Conclusion

In conclusion it is important to consider important factors such as ‘which system is most advantageous for whom? And what is most advantageous for the product originator.

Japan benefits from the following:

• High flexibility in extensions
• No upper limit after approval
• Opportunities for extension even with additional approvals

It is important to understand how Japan’s patent term extension system differs from those in the U.S. and EU. Furthermore, strategically applying for patent term extensions for multiple approvals of a single product in Japan is believed to maximize the product’s value and increase the likelihood of successful licensing deals.

Reference

Nakanishi S. Overview and Actual Operation of Patent Term Extension Systems in Japan, the U.S., and the EU. Public Economics Program, Graduate School of International Public Policy, Hitotsubashi University, Japan. August 2009. (Japanese)

Author:
Toshiaki Nagafuji, PhD, RPh
Exec Officer, CTO, Head of Development Strategy Business